Gallstone-dissolving agents.
It can be anticipated that most new therapies will generate considerable excitement and optimism when introduced. This is usually tempered with time as additional clinical experience is gained and therapeutic limitations and adverse effects are realized. All areas in the nonsurgical management of gallstones have experienced this course--some, such as ESWL, rather meteorically. Perspective, however, is important and may allow the appropriate use of each of these modalities in the correct clinical setting. For example, ursodiol when given in sufficient dose to nonobese patients with small radiolucent stones, could be expected to effect partial or complete dissolution in as many as 75% of patients, with minimal or no adverse effects and in a cost-effective manner. Contact dissolution using MTBE has been shown to be safe and generally effective but requires diligent characterization of stones to avoid those that are pigmented or heavily calcified. Similarly, ESWL combined with oral bile acids may be consistently effective if treatment is restricted to patients with acceptable cholesterol stone burdens and if treatment can be safely continued until fragments are substantially reduced. Continued experience with each of these treatment options, along with advances in research providing new solvents and technologies or in preventing recurrence, is likely to establish this field in an appropriately optimistic light.
Peine
C J
CJ
University of Minnesota and Hennepin County Medical Center, Minneapolis.
D001647:Bile Acids and Salts / Q000494:pharmacology / Q000627:therapeutic use*; D002210:Caprylates; D002769:Cholelithiasis / Q000188:drug therapy*; D004987:Ethers / Q000627:therapeutic use; D005989:Glycerides / Q000627:therapeutic use; D006801:Humans; D008738:Methyl Ethers; D012008:Recurrence; D012997:Solvents / Q000627:therapeutic use*
D001647:Bile Acids and Salts; D002210:Caprylates; D004987:Ethers; D005989:Glycerides; D008738:Methyl Ethers; D012997:Solvents; C043243:methyl tert-butyl ether; C025343:monooctanoin